Trial · NCT00687713

Phase 2, Double-Blind, Placebo-Controlled Trial of Bupropion for Methamphetamine Dependence

NCT00687713, Phase 2, Completed, National Institute on Drug Abuse (NIDA); results first posted 2017-02-15

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Phase 2, Double-Blind, Placebo-Controlled Trial of Bupropion for Methamphetamine Dependence. Trials, record NCT00687713. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00687713

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Phase 2, Double-Blind, Placebo-Controlled Trial of Bupropion for Methamphetamine Dependence
NCT number: NCT00687713
Status: Completed
Phases: Phase 2
Enrollment: 200 participants, actual
Lead sponsor: National Institute on Drug Abuse (NIDA)
Conditions: Methamphetamine Dependence
Interventions: Bupropion, Placebo
First posted: 2008-06-02
Last updated: 2017-03-21
Results first posted: 2017-02-15

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Number of Subjects Showing Abstinence	Weeks 11 and 12	The primary efficacy outcome measure was a measurement of treatment success or failure, where a subject who successfully achieved two weeks of abstinence during the last two weeks of investigational product dosing (Weeks 11 and 12) was scored as a success.
Secondary	Treatment Success Among Subjects With 18 or Less Days of Methamphetamine Use	30 days	The study population for this outcome measure is defined as those participants with methamphetamine dependence who report using methamphetamine 18 or less days during the 30 days prior to signing consent.

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Number of Subjects Showing Abstinence	Weeks 11 and 12		Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Treatment Success Among Subjects With 18 or Less Days of Methamphetamine Use	30 days		Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.gov

Results by group4

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Units
Number of Subjects Showing Abstinence	Bupropion	14	Participants
Number of Subjects Showing Abstinence	Placebo	20	Participants
Treatment Success Among Subjects With 18 or Less Days of Methamphetamine Use	Bupropion	65	Participants
Treatment Success Among Subjects With 18 or Less Days of Methamphetamine Use	Placebo	76	Participants

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Bupropion	100
Overall Study	STARTED	Placebo	104
Overall Study	COMPLETED	Bupropion	68
Overall Study	COMPLETED	Placebo	64
Overall Study	NOT COMPLETED	Bupropion	32
Overall Study	NOT COMPLETED	Placebo	40

Source ClinicalTrials.gov

Adverse events12

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Nausea	Gastrointestinal disorders	Bupropion	9	100	14
other	Nausea	Gastrointestinal disorders	Placebo	23	104	27
other	Headache	Nervous system disorders	Bupropion	37	100	68
other	Headache	Nervous system disorders	Placebo	43	104	88
other	Nasopharyngitis	Infections and infestations	Bupropion	4	100	5
other	Nasopharyngitis	Infections and infestations	Placebo	12	104	12
other	Back Pain	Musculoskeletal and connective tissue disorders	Bupropion	18	100	19
other	Back Pain	Musculoskeletal and connective tissue disorders	Placebo	11	104	13
other	Cough	Respiratory, thoracic and mediastinal disorders	Bupropion	16	100	17
other	Cough	Respiratory, thoracic and mediastinal disorders	Placebo	14	104	17

1 to 10 of 12Source ClinicalTrials.gov

See all 12 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Bupropion
Total, all-cause mortality	Placebo
Total, other adverse events	Bupropion	83	100
Total, other adverse events	Placebo	93	104
Total, serious adverse events	Bupropion	1	100
Total, serious adverse events	Placebo	3	104

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
25818061	BACKGROUND

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons3

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Bupropion vs Placebo: Treatment Success Among Subjects With 18 or Less Days of Methamphetamine Use	Trial comparisons
Bupropion vs Placebo: Number of Subjects Showing Abstinence	Trial comparisons
Bupropion vs Placebo: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00687713

GET https://conductscience.org/api/trials/v1/NCT00687713/registered

API reference For AI assistants